| Day 2 – June 24, 2022 | Atypical Hemolytic Uremic Syndrome | ||||
|---|---|---|---|---|
Session 4:What Have We Learnt from Animal Models? |
08:30 | Modeling aHUS in Genetic Mouse Models | Wenchao Song | United States |
| 08:50 | Role of Complement in the Pathophysiology of STEC-HUS: Evidence from a Mouse Model | Carlamaria Zoja | Italy | |
| 09:20 | Q&A Discussion | |||
Session 5:Advances in Pathophysiology |
09:40 | Genetic Basis of aHUS | David Kavanagh | United Kingdom |
| 10:00 | Common Genetic Susceptibility Factors in aHUS | Elena Goicoechea de Jorges | Spain | |
| 10:20 | Anti-FH Antibodies Associated HUS | Arvind Bagga | India | |
| 10:40 | aHUS: Why the Kidney? | Lubka Roumenina | France | |
| 11:00 | Q&A Discussion | |||
| Coffee Break | 11:20 | Coffee Break and Poster Viewing | ||
Session 6:Clinical- Unanswered Questions |
11:40 | Primary and Secondary aHUS. Still Worth Discussing? | Giovanni Montini | Italy |
| 12:00 | Postpartum Renal Cortical Necrosis and aHUS | Raja Ramachandran | India | |
| 12:20 | Monitoring Complement Dysregulation in aHUS | Miriam Galbusera | Italy | |
| 12:40 | Q&A Discussion | |||
| Lunch Break | 13:10 | Lunch and Poster Viewing | ||
| Therapy | ||||
Session 7:When and How to Inhibit C5 in Complement-mediated Rare Nephropathies |
14:00 | Eculizumab in Primary and Secondary aHUS: Who, When, and How Long? | Sjoerd Timmermans | The Netherlands |
| 14:20 | Eculizumab in Primary and Secondary aHUS: Who, When, and How Long? | Giuseppe Remuzzi | Italy | |
| 14:40 | Impact of C5 Blockade on Post-transplant Outcomes and Renal Epidemiology of aHUS | Christophe Legendre | France | |
| 15:00 | Oral Presentation from Abstract Selection Atypical Renal Recovery From Atypical Hemolytic Uremic Syndrome |
Bianca Covella | Italy | |
| 15:10 | Q&A Discussion | |||
| Coffee Break | 15:30 | Coffee Break and Poster Viewing | ||
Session 8:When and How to Inhibit C3 in Complement-mediated Rare Nephropathies |
16:00 | Manipulating the Early Steps of Complement Cascade: Emerging Drugs, Potential Risks, and Benefits | Joshua Thurman | United States |
| 16:20 | Lessons from Studies in Mouse Models of C3G | Ariela Benigni | Italy | |
| 16:40 | Targeting C3, CFD, or CFB in C3G, Preliminary Results of Clinical Trials in Patients with C3G/IC-MPGN | Erica Daina | Italy | |
| 17:00 | Oral presentation from abstract selection BCX9930, An Oral Factor D Inhibitor, Suppresses Complement Alternative Pathway Activity In Patients With Complement 3 Glomerulopathy |
Xilin Chen | USA | |
| 17:10 | Q&A Discussion | |||
| Keynote Lecture | 17:30 | HUS in 2022 | Fadi Fakhouri | Switzerland |
Day 2
© copyright 2022 ISN